| Major Depressive Disorder
Caplyta vs Viibyrd
Side-by-side clinical, coverage, and cost comparison for major depressive disorder.Deep comparison between: Caplyta vs Viibryd with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsViibryd has a higher rate of injection site reactions vs Caplyta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Viibryd but not Caplyta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Caplyta
Viibryd
At A Glance
Oral
Once daily
Atypical antipsychotic
Oral
Daily
SSRI / 5-HT1A partial agonist
Indications
- Schizophrenia
- Depression, Bipolar
- Major Depressive Disorder
- Major Depressive Disorder
Dosing
Schizophrenia, Depression, Bipolar, Major Depressive Disorder 42 mg orally once daily with or without food; no dose titration needed.
With strong CYP3A4 inhibitors Reduce to 10.5 mg once daily.
With moderate CYP3A4 inhibitors Reduce to 21 mg once daily.
Moderate or severe hepatic impairment Reduce to 21 mg once daily (Child-Pugh class B or C).
Major Depressive Disorder Start at 10 mg once daily with food for 7 days, then increase to 20 mg once daily; may increase up to 40 mg once daily after a minimum of 7 days between dosage increases; target dose is 20-40 mg once daily with food.
Contraindications
- History of hypersensitivity reaction to lumateperone or any component of CAPLYTA (including pruritus, rash, and urticaria)
- Concomitant use or within 14 days of stopping MAOIs, including linezolid or intravenous methylene blue, due to increased risk of serotonin syndrome
Adverse Reactions
Most common (>=5%) Somnolence/sedation, dizziness, nausea, dry mouth, headache, fatigue, diarrhea, vomiting
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension and syncope, seizures, suicidal thoughts and behaviors, cerebrovascular adverse reactions including stroke in elderly patients with dementia-related psychosis
Postmarketing Burning sensation, including skin burning sensation
Most common (>=5%) Diarrhea, nausea, vomiting, insomnia
Serious Suicidal thoughts and behaviors, serotonin syndrome, increased risk of bleeding, activation of mania or hypomania, discontinuation syndrome, seizures, angle-closure glaucoma, hyponatremia, sexual dysfunction
Postmarketing Irritability, sleep paralysis, hallucinations, suicide attempt, suicidal ideation, rash, urticaria, drug eruption, acute pancreatitis, anosmia, hyposmia
Pharmacology
Lumateperone is an atypical antipsychotic whose mechanism may be mediated through antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors; it also has moderate SERT inhibitory activity and moderate binding affinity for dopamine D1, D4, and adrenergic alpha-1 receptors.
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist thought to enhance serotonergic activity in the CNS through selective inhibition of serotonin reuptake; its exact mechanism in treating major depressive disorder is not fully understood.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Caplyta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (2/12)
Viibryd
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (9/12) · Qty limit (1/12)
UnitedHealthcare
Caplyta
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (6/8)
Viibryd
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Caplyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Viibryd
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Schizophrenia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Viibryd.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CaplytaView full Caplyta profile
ViibrydView full Viibryd profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.